Regorafenib is a multi-kinase inhibitor that targets various receptor tyrosine kinases, and research has shown that it can reduce the number of immunosuppressive regulatory T cells and tumor-associated macrophages (27, 28). The gene discussed is NTRK1; the disease is neoplasm.